BioCentury
BioCentury
YouTubeLinkedInXRSS
ARTICLE | Distillery Therapeutics

TMC1 gene editing therapy for dominant progressive hearing loss

Claire Quang
July 25, 2019 9:42 PM UTC

INDICATION: Hearing loss...

BCIQ Company Profiles

Boston Children's Hospital

Harvard Medical School

BCIQ Target Profiles

CRISPR-associated protein 9 (Cas9)

Transmembrane channel-like-1 (TMC1)

BCIQ Company Profiles

Boston Children's Hospital

Harvard Medical School

BCIQ Target Profiles

CRISPR-associated protein 9 (Cas9)

Transmembrane channel-like-1 (TMC1)

About BioCentury

Privacy & Legal

Contact

About BioCentury

Company Overview
Management
Editorial & Research
Scientific Advisory Board

Privacy & Legal

User Agreement
Terms of Use
Privacy Policy
Use of Images & Market Data
Reprints & Permissions

Contact

Contact Us
Advertising & Sponsorship
Customer Resource Center
Career Opportunities
Forgot Password
YouTubeLinkedInXRSS
BioCentury
© 2025 BioCentury Inc. All Rights Reserved.
Copyright © 2025 BioCentury Inc. All Rights Reserved.
YouTubeLinkedInXRSS